Trial Profile
Changes in annualized cortical thickness slowing cortical atrophy with Alemtuzumab treatment in patients with Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2016
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 26 Nov 2016 New trial record